{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:00:38Z","timestamp":1792602038241,"version":"4.5.0"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003069","name":"Instituto Polit\u00e9cnico Nacional","doi-asserted-by":"publisher","award":["SIP20242814, SIP20250306, SIP20251096"],"award-info":[{"award-number":["SIP20242814, SIP20250306, SIP20251096"]}],"id":[{"id":"10.13039\/501100003069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Humanidades, Ciencias y Tecnolog\u00edas","doi-asserted-by":"publisher","award":["2051579, 2046158, 2048244"],"award-info":[{"award-number":["2051579, 2046158, 2048244"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Dengue fever represents an escalating global health threat, as unprecedented outbreaks expose significant limitations of current vaccine strategies. Conventional live-attenuated dengue vaccines, while partially efficacious, face critical hurdles including serotype imbalances and antibody-dependent enhancement (ADE). This review critically assesses virus-like particle (VLP) vaccines as a promising alternative, providing safer, non-replicating platforms that mimic viral structure without risks associated with live replication. Technological advancements in recombinant expression systems have improved VLP yield, stability, and scalability, addressing deployment obstacles. Recent preclinical studies demonstrate that tetravalent dengue VLP vaccines induce balanced neutralizing antibodies across all serotypes, effectively circumventing ADE in animal models. These findings suggest superior safety and robust immune responses, potentially surpassing live-attenuated and mRNA-based vaccines. We emphasize advancements in VLP vaccine technology, including novel tetravalent particle designs engineered to exclude ADE-related immunopathogenic components (prM protein), innovative stability-enhancing formulation techniques, and cost-effective recombinant production platforms (yeast and plant-based systems). Additionally, this review proposes novel deployment strategies, such as regional manufacturing hubs, standardized modular VLP platforms, adaptive clinical trial frameworks leveraging surrogate endpoints, and strengthened international coordination for equitable vaccine distribution. Integrating these scientific innovations and practical strategies positions dengue VLP vaccines as pivotal next-generation solutions for global dengue prevention.<\/jats:p>","DOI":"10.3389\/fcimb.2025.1614805","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T05:23:54Z","timestamp":1750051434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Overcoming dengue vaccine challenges through next-generation virus-like particle immunization strategies"],"prefix":"10.3389","volume":"15","author":[{"given":"Mariana","family":"Parra-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"N\u00e1jera-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Peralta-Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley J.","family":"Gutierrez-Onofre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Garcia-Atutxa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Villanueva-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01601-22","article-title":"Comparative efficacy of mayaro virus-like particle vaccines produced in insect or mammalian cells","volume":"97","author":"Abbo","year":"2023","journal-title":"J. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e02322","DOI":"10.1128\/jvi.02322-24","article-title":"Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage","volume":"99","author":"Abbo","year":"2025","journal-title":"J. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/v17020212","article-title":"Current dengue virus vaccine developments and future directions","volume":"17","author":"Anumanthan","year":"2025","journal-title":"Viruses."},{"key":"B4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00705-009-0484-8","article-title":"Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris","volume":"154","author":"Bazan","year":"2009","journal-title":"Arch. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.1016\/j.vaccine.2018.10.072","article-title":"Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature","volume":"36","author":"Boigard","year":"2018","journal-title":"Vaccine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1126\/science.abc7303","article-title":"Antibody fucosylation predicts disease severity in secondary dengue infection","volume":"372","author":"Bournazos","year":"2021","journal-title":"Science."},{"key":"B10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/applmicrobiol3030056","article-title":"Yeast and virus-like particles: A perfect or imperfect couple","volume":"3","author":"Brachelente","year":"2023","journal-title":"Appl. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"19234","DOI":"10.1038\/srep19234","article-title":"Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization","volume":"6","author":"Brune","year":"2016","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1080\/21645515.2018.1469591","article-title":"Development of new hepatitis E vaccines","volume":"14","author":"Cao","year":"2018","journal-title":"Hum. Vaccines Immunotherapeutics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"205:116","DOI":"10.1016\/j.jviromet.2014.04.019","article-title":"An optimized expression vector for improving the yield of dengue virus-like particles from transfected insect cells","author":"Charoensri","year":"2014","journal-title":"J. Virological Methods"},{"key":"B14","volume-title":"A Study of a Tetravalent Dengue Vaccine (TAK-003) in Healthy Children","year":"2016"},{"key":"B15","article-title":"Study of a tetravalent dengue vaccine (TAK-003) for healthy children (Identifier: NCT03771963)","volume":"98","year":"2018","journal-title":"U.S. Natl. Library Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.vaccine.2019.12.012","article-title":"The potential impact of dengue vaccination with, and without, pre-vaccination screening","volume":"38","author":"Coudeville","year":"2020","journal-title":"Vaccine."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jip.2011.05.003","article-title":"A fast track influenza virus vaccine produced in insect cells","volume":"107","author":"Cox","year":"2011","journal-title":"J. Invertebrate Pathology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J. Immunological Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am. J. Trop. Med. Hygiene."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1016\/j.vaccine.2013.08.088","article-title":"Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA","volume":"31","author":"Dayan","year":"2013","journal-title":"Vaccine."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004386","article-title":"Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera","volume":"10","author":"De Alwis","year":"2014","journal-title":"PloS Pathog."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087837","article-title":"Vaccination of mice using the west nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge","volume":"9","author":"De Filette","year":"2014","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e01415","DOI":"10.1128\/JVI.01415-20","article-title":"Zika virus-like particles bearing a covalent dimer of envelope protein protect mice from lethal challenge","volume":"95","author":"De Lorenzo","year":"2020","journal-title":"Heise MT editor. J. Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/bioengineering8090119","article-title":"Pichia pastoris (Komagataella phaffii) as a Cost-Effective Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs)","volume":"8","author":"De S\u00e1 Magalh\u00e3es","year":"2021","journal-title":"Bioengineering."},{"key":"B26","doi-asserted-by":"publisher","first-page":"100127","DOI":"10.1016\/j.hsr.2023.100127","article-title":"Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2","volume":"9","author":"Dhawan","year":"2023","journal-title":"Health Sci. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J. Transl. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00253-024-13064-y","article-title":"Low-temperature culture enhances production of flavivirus virus-like particles in mammalian cells","volume":"108","author":"Fan","year":"2024","journal-title":"Appl. Microbiol Biotechnol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1007\/s00705-017-3450-x","article-title":"Recent progress in the development of white spot syndrome virus vaccines for protecting shrimp against viral infection","volume":"162","author":"Feng","year":"2017","journal-title":"Arch. Virol."},{"key":"B30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-253055-5.50005-0","article-title":"Structure and composition of viruses","volume-title":"Veterinary Virology","author":"Fenner","year":"1987"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002181","article-title":"The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): A model comparison study","volume":"13","author":"Flasche","year":"2016","journal-title":"PloS Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/nn100869j","article-title":"Directed self-assembly of nanoparticles","volume":"4","author":"Grzelczak","year":"2010","journal-title":"ACS nano"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123805","article-title":"Platforms, advances, and technical challenges in virus-like particles-based vaccines","volume":"14","author":"Gupta","year":"2023","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3390\/v2122649","article-title":"The complexity of antibody-dependent enhancement of dengue virus infection","volume":"2","author":"Guzman","year":"2010","journal-title":"Viruses."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1056\/NEJMoa2201300","article-title":"Efficacy and safety of a recombinant plant-based adjuvanted covid-19 vaccine","volume":"386","author":"Hager","year":"2022","journal-title":"N Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.1016\/j.ijregi.2024.100459","article-title":"Global landmark: 2023 marks the worst year for dengue cases with millions infected and thousands of deaths reported","volume":"13","author":"Haider","year":"2024","journal-title":"IJID Regions."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/vaccines11071218","article-title":"Application of baculovirus expression vector system (BEVS) in vaccine development","volume":"11","author":"Hong","year":"2023","journal-title":"Vaccines."},{"key":"B40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cmi.2012.61","article-title":"TLR signaling in B-cell development and activation","volume":"10","author":"Hua","year":"2013","journal-title":"Cell Mol. Immunol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8378","article-title":"Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity","volume":"371","author":"Larsen","year":"2021","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65131","article-title":"Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data","volume":"10","author":"Laydon","year":"2021","journal-title":"eLife."},{"key":"B43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1046\/j.1365-2796.2003.01140.x","article-title":"DNA vaccines: a review","volume":"253","author":"Liu","year":"2003","journal-title":"J. Intern Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2455807","DOI":"10.1080\/21645515.2025.2455807","article-title":"Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system","volume":"21","author":"Liu","year":"2025","journal-title":"Hum. Vaccines Immunotherapeutics."},{"key":"B45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11262-009-0418-2","article-title":"Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties","volume":"40","author":"Liu","year":"2010","journal-title":"Virus Genes."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J. Infect. Diseases."},{"key":"B47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/bit.v111.3","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotech. Bioengineering."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064595","article-title":"Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies","volume":"8","author":"Mani","year":"2013","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum. Vaccin Immunother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.3390\/plants13243564","article-title":"Virus-like particles produced in plants: A promising platform for recombinant vaccine development","volume":"13","author":"Mardanova","year":"2024","journal-title":"Plants (Basel)."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02931","article-title":"A universal plug-and-display vaccine carrier based on HBsAg VLP to maximize effective antibody response","volume":"10","author":"Marini","year":"2019","journal-title":"Front. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/594120","article-title":"Development of an IP-free biotechnology platform for constitutive production of HPV16 L1 capsid protein using the pichia pastoris PGK1 promoter","volume":"2015","author":"Mariz","year":"2015","journal-title":"BioMed. Res. Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.3390\/ijms23158579","article-title":"Virus-like particles: fundamentals and biomedical applications","volume":"23","author":"Mej\u00eda-M\u00e9ndez","year":"2022","journal-title":"IJMS."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1128\/JVI.00787-15","article-title":"Dengue virus inhibition of autophagic flux and dependency of viral replication on proteasomal degradation of the autophagy receptor p62","volume":"89","author":"Metz","year":"2015","journal-title":"J. Virol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.jvacx.2022.100142","article-title":"Safety and immunogenicity of a single dose, live-attenuated \u2018tetravalent dengue vaccine\u2019 in healthy Indian adults; a randomized, double-blind, placebo controlled phase I\/II trial","volume":"10","author":"Mohanty","year":"2022","journal-title":"Vaccine: X."},{"key":"B57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1473-3099(24)00376-1","article-title":"Efficacy and safety of Butantan-DV in participants aged 2\u201359 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil","volume":"24","author":"Nogueira","year":"2024","journal-title":"Lancet Infect. Diseases."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.21.631174","article-title":"Structural insights into immature dengue virus-like particles revealed by cryo-EM and molecular dynamics simulations","author":"Palur","year":"2025"},{"key":"B60","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/v17020148","article-title":"The role of plant virus-like particles in advanced drug delivery and vaccine development: structural attributes and application potential","volume":"17","author":"Peralta-Cuevas","year":"2025","journal-title":"Viruses."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173328","article-title":"TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies","volume":"134","author":"Pierce","year":"2024","journal-title":"J. Clin. Investigation."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8411","DOI":"10.1038\/s41598-020-65288-3","article-title":"Molecular basis of differential stability and temperature sensitivity of ZIKA versus dengue virus protein shells","volume":"10","author":"Pindi","year":"2020","journal-title":"Sci. Rep."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001831","article-title":"Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art","volume":"104","author":"Pintado Silva","year":"2023","journal-title":"J. Gen. Virol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/pbi.13501","article-title":"Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice","volume":"19","author":"Ponndorf","year":"2021","journal-title":"Plant Biotechnol. J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"44a","DOI":"10.1016\/j.bpj.2022.11.451","article-title":"An integrative and multiscale approach to study dengue virus-like particle dynamics","volume":"122","author":"Raghuvamsi Palur","year":"2023","journal-title":"Biophys. J."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000718","article-title":"Immature dengue virus: A veiled pathogen","volume":"6","author":"Rodenhuis-Zybert","year":"2010","journal-title":"PloS Pathog."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002367","article-title":"On the effect of thermodynamic equilibrium on the assembly efficiency of complex multi-layered virus-like particles (VLP): the case of rotavirus VLP","volume":"8","author":"Rold\u00e3o","year":"2012","journal-title":"PloS Comput. Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/vaccines12080874","article-title":"Preclinical evaluation of novel sterically optimized VLP-based vaccines against all four DENV serotypes","volume":"12","author":"Rothen","year":"2024","journal-title":"Vaccines."},{"key":"B69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12560-015-9198-0","article-title":"Zeta potential and aggregation of virus-like particle of human norovirus and feline calicivirus under different physicochemical conditions","volume":"7","author":"Samandoulgou","year":"2015","journal-title":"Food Environ. Virol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1016\/j.vaccine.2024.03.034","article-title":"CHO cells for virus-like particle and subunit vaccine manufacturing","volume":"42","author":"Sanchez-Martinez","year":"2024","journal-title":"Vaccine."},{"key":"B73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4161\/hv.2.4.2989","article-title":"Evaluation of the thermal stability of gardasil\u00ae","volume":"2","author":"Shank-Retzlaff","year":"2006","journal-title":"Hum. Vaccines."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38970","article-title":"Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody","volume":"7","author":"Shen","year":"2018","journal-title":"eLife."},{"key":"B75","doi-asserted-by":"publisher","first-page":"114032","DOI":"10.1016\/j.intimp.2025.114032","article-title":"Heterologous Prime-Boost immunization with Adenoviral vector and recombinant subunit vaccines strategies against dengue virus type2","volume":"148","author":"Shoushtari","year":"2025","journal-title":"Int. Immunopharmacology."},{"key":"B76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4939-7808-3_5","article-title":"Planta production of fluorescent filamentous plant virus-based nanoparticles","volume-title":"Virus-Derived Nanoparticles for Advanced Technologies","author":"Shukla","year":"2018"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/infdis\/jiaa406","article-title":"Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: A randomized, placebo-controlled, phase 2 study","volume":"225","author":"Sirivichayakul","year":"2022","journal-title":"J. Infect. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl. J. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1473-3099(16)00026-8","article-title":"The global burden of dengue: an analysis from the Global Burden of Disease Study 2013","volume":"16","author":"Stanaway","year":"2016","journal-title":"Lancet Infect. Diseases."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1086\/522864","article-title":"Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection","volume":"196","year":"2007","journal-title":"J. Infect. Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1016\/j.vaccine.2022.04.021","article-title":"Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines","volume":"40","author":"Thompson","year":"2022","journal-title":"Vaccine."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e00239","DOI":"10.1128\/jvi.00239-24","article-title":"A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates","volume":"98","author":"Thoresen","year":"2024","journal-title":"J. Virol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12934-014-0134-z","article-title":"Secreted production of assembled Norovirus virus-like particles from Pichia pastoris","volume":"13","author":"Tom\u00e9-Amat","year":"2014","journal-title":"Microb Cell Fact."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Global Health"},{"key":"B85","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2015.01005","article-title":"Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies","volume":"6","author":"Tripathi","year":"2015","journal-title":"Front. Microbiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/14760584.2022.2085565","article-title":"The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing","volume":"21","author":"Trombetta","year":"2022","journal-title":"Expert Rev. Vaccines."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1016\/j.vaccine.2015.05.016","article-title":"Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2","volume":"33","author":"Tumban","year":"2015","journal-title":"Vaccine."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum. Vaccines Immunotherapeutics."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e01181","DOI":"10.1128\/JVI.01181-17","article-title":"An envelope-modified tetravalent dengue virus-like-particle vaccine has implications for flavivirus vaccine design","volume":"91","author":"Urakami","year":"2017","journal-title":"J. Virol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13568-022-01353-6","article-title":"Humoral immune response induced with dengue virus-like particles serotypes 1 and 4 produced in silkworm","volume":"12","author":"Utomo","year":"2022","journal-title":"AMB Expr."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01956","article-title":"Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus","volume":"10","author":"Vald\u00e9s","year":"2019","journal-title":"Front. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1016\/j.vaccine.2023.05.010","article-title":"The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine","volume":"41","author":"Vesikari","year":"2023","journal-title":"Vaccine."},{"key":"B93","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jip.2011.05.004","article-title":"Large-scale production and purification of VLP-based vaccines","volume":"107","author":"Vicente","year":"2011","journal-title":"J. Invertebrate Pathology."},{"key":"B94","doi-asserted-by":"publisher","first-page":"114403","DOI":"10.1016\/j.jviromet.2021.114403","article-title":"Combined truncations at both N- and C-terminus of human papillomavirus type 58 L1 enhanced the yield of virus-like particles produced in a baculovirus system","volume":"301","author":"Wang","year":"2022","journal-title":"J. Virological Methods"},{"key":"B95","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00103-019-03060-3","article-title":"Dengue vaccine development: status and future","volume":"63","author":"Wilder-Smith","year":"2020","journal-title":"Bundesgesundheitsbl."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e02482","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J. Virol."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01415","article-title":"Dengue virus glycosylation: what do we know","volume":"8","author":"Yap","year":"2017","journal-title":"Front. Microbiol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.virol.2006.03.021","article-title":"Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies","volume":"351","author":"Ye","year":"2006","journal-title":"Virology."},{"key":"B99","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.phrp.2014.08.005","article-title":"Cloning and expression of recombinant tick-borne encephalitis virus-like particles in pichia pastoris","volume":"5","author":"Yun","year":"2014","journal-title":"Osong Public Health Res. Perspectives."},{"key":"B100","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.coviro.2013.05.004","article-title":"Virus-induced humoral immunity: on how B cell responses are initiated","volume":"3","author":"Zabel","year":"2013","journal-title":"Curr. Opin. Virology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"18:702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1614805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T05:23:56Z","timestamp":1750051436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1614805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":101,"alternative-id":["10.3389\/fcimb.2025.1614805"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1614805","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"article-number":"1614805"}}